Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer

Laura Muñoz-Moreno, Andrew V Schally, Juan C. Prieto, M. José Carmena, Ana M. Bajo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. Methods: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists. Results: GHRH-R antagonists decreased cell viability and provoked a reduction in proliferation in LNCaP and PC3 cells. Moreover, GHRH-R antagonists caused a time-dependent increase of cell adhesion in all three cell lines and retarded the wound closure with the highest value with MIA-690 in PC3 cells. GHRH-R antagonists also provoked a large number of cells in SubG0 phase revealing an increase in apoptotic cells in PC3 cell line. Conclusions: Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.

Original languageEnglish (US)
JournalProstate
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hormone Antagonists
Prostatic Neoplasms
Cell Adhesion
Cell Line
Catenins
Neoplasms
Proliferating Cell Nuclear Antigen
Cadherins
Vascular Endothelial Growth Factor A
somatotropin releasing hormone receptor
Prostate
Cell Survival
Cell Count
Cell Proliferation
Phenotype
Wounds and Injuries
Therapeutics

Keywords

  • Angiogenesis
  • Antagonists
  • Cell adhesion
  • Cell proliferation
  • GHRH-R
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. / Muñoz-Moreno, Laura; Schally, Andrew V; Prieto, Juan C.; Carmena, M. José; Bajo, Ana M.

In: Prostate, 01.01.2018.

Research output: Contribution to journalArticle

@article{12e1dc88a1ce4581a61e34ed8d57da05,
title = "Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer",
abstract = "Background: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. Methods: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists. Results: GHRH-R antagonists decreased cell viability and provoked a reduction in proliferation in LNCaP and PC3 cells. Moreover, GHRH-R antagonists caused a time-dependent increase of cell adhesion in all three cell lines and retarded the wound closure with the highest value with MIA-690 in PC3 cells. GHRH-R antagonists also provoked a large number of cells in SubG0 phase revealing an increase in apoptotic cells in PC3 cell line. Conclusions: Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.",
keywords = "Angiogenesis, Antagonists, Cell adhesion, Cell proliferation, GHRH-R, Prostate cancer",
author = "Laura Mu{\~n}oz-Moreno and Schally, {Andrew V} and Prieto, {Juan C.} and Carmena, {M. Jos{\'e}} and Bajo, {Ana M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/pros.23648",
language = "English (US)",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer

AU - Muñoz-Moreno, Laura

AU - Schally, Andrew V

AU - Prieto, Juan C.

AU - Carmena, M. José

AU - Bajo, Ana M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. Methods: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists. Results: GHRH-R antagonists decreased cell viability and provoked a reduction in proliferation in LNCaP and PC3 cells. Moreover, GHRH-R antagonists caused a time-dependent increase of cell adhesion in all three cell lines and retarded the wound closure with the highest value with MIA-690 in PC3 cells. GHRH-R antagonists also provoked a large number of cells in SubG0 phase revealing an increase in apoptotic cells in PC3 cell line. Conclusions: Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.

AB - Background: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. Methods: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists. Results: GHRH-R antagonists decreased cell viability and provoked a reduction in proliferation in LNCaP and PC3 cells. Moreover, GHRH-R antagonists caused a time-dependent increase of cell adhesion in all three cell lines and retarded the wound closure with the highest value with MIA-690 in PC3 cells. GHRH-R antagonists also provoked a large number of cells in SubG0 phase revealing an increase in apoptotic cells in PC3 cell line. Conclusions: Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.

KW - Angiogenesis

KW - Antagonists

KW - Cell adhesion

KW - Cell proliferation

KW - GHRH-R

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85046740241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046740241&partnerID=8YFLogxK

U2 - 10.1002/pros.23648

DO - 10.1002/pros.23648

M3 - Article

JO - Prostate

JF - Prostate

SN - 0270-4137

ER -